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Support measures currently represent the mainstay of treatment for fulminant myo-
carditis, while effective and safe anti-inflammatory therapies remain an unmet clinical 
need. However, clinical and experimental evidence indicates that inhibition of the pro- 
inflammatory cytokine interleukin 1 (IL-1) is effective against both myocardial inflamma-
tion and contractile dysfunction. We thus evaluated treatment with the IL-1 receptor 
antagonist anakinra in a case of heart failure secondary to fulminant myocarditis. 
A 65-year-old man with T cell lymphoma developed fulminant myocarditis presenting 
with severe biventricular failure and cardiogenic shock requiring admittance to the inten-
sive care unit and mechanical circulatory and respiratory support. Specifically, acute 
heart failure and cardiogenic shock were initially treated with non-invasive ventilation 
and mechanical circulatory support with an intra-aortic balloon pump. Nevertheless, 
cardiac function deteriorated further, and there were no signs of improvement. Treatment 
with anakinra, the recombinant form of the naturally occurring IL-1 receptor antagonist, 
was started at a standard subcutaneous dose of 100 mg/day. We observed a dramatic 
clinical improvement within 24 h of initiating anakinra. Prompt, progressive amelioration 
of cardiac function allowed weaning from mechanical circulatory and respiratory support 
within 72 h of anakinra administration. Recent studies point at inhibition of IL-1 activity as 
an attractive treatment option for both myocardial inflammation and contractile dysfunc-
tion. Furthermore, IL-1 receptor blockade with anakinra is characterized by an extremely 
rapid onset of action and remarkable safety and may thus be suitable for the treatment 
of patients critically ill with myocarditis.
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INtRoDUCtIoN
A 65-year-old Caucasian man was hospitalized for low-grade fever, fatigue, and unintentional weight 
loss. He had a history of elevated arterial blood pressure and benign prostatic hyperplasia; family and 
social history were unremarkable. At admission, vitals were normal. Physical examination revealed a 
moderately enlarged spleen, a finding confirmed at bedside abdominal ultrasound (bipolar diameter 
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15 cm). Blood tests showed mild leukocytosis (15,000/mm3, neu-
trophils 88%), anemia (Hb 9.5 g/dL), thrombocytopenia (70,000/
mm3), high levels of inflammatory markers C-reactive protein 
(CRP, 104 mg/L, normal values 0–6 mg/L) and ferritin (515 ng/
mL, normal values 15–150  ng/mL), and mildly elevated liver 
transaminases and serum lactate dehydrogenase. A whole-body 
computed tomography scan revealed confluent areas of reduced 
tissue density in the liver and spleen, compatible with malignancy, 
and multiple abdominal lymphadenopathies. In the hypothesis of 
hematologic neoplasm, a bone marrow biopsy was performed. 
Histologic examination was eventually diagnostic for anaplastic 
T  cell lymphoma; macrophages phagocytizing hematopoietic 
cells were concomitantly observed.
Shortly after this procedure, the patient acutely developed 
fever, hypotension, and dyspnea. Blood pressure dropped to 
80/45  mmHg, respiratory rate was 34 breaths per minute, and 
oxygen saturation was 89% while he was breathing ambient air. 
Biochemical analyses showed marked leukocytosis with neutro-
philia (20,000/mm3, neutrophils 90%), elevated CRP (150 mg/L, 
normal values <6), and troponin T (78 ng/L, normal values <38). 
Blood and urine cultures were negative, and procalcitonin serum 
levels were normal. Electrocardiogram showed sinus tachycar-
dia with T wave alterations. A transthoracic echocardiogram 
(TTE) revealed a severely depressed contractile function in both 
ventricles, with a left ventricle ejection fraction (LVEF) of 25%. 
A  repeated whole-body computed tomography documented 
initial pulmonary edema but no remarkable findings in addition 
to the previously documented liver and spleen abnormalities. 
Heart catheterization revealed normal coronary anatomy with-
out significant stenosis. Myocardial biopsy was not performed. 
A comprehensive search for autoantibodies and viral genome 
testing on blood and sputum were negative.
The patient was admitted to the intensive care unit and received 
intravenous dobutamine, furosemide, and non-invasive ventila-
tion with continuous positive air pressure. Due to persistent 
hypotension refractory to positive inotropic agents, urgent posi-
tioning of an intra-aortic balloon pump (IABP) was required to 
maintain the cardiac output. However, during the following day, 
no signs of myocardial recovery were observed, and the severe 
biventricular dysfunction further worsened (LVEF < 20%).
BaCKGRoUND
Fulminant myocarditis is an inflammatory disease of the myo-
cardium leading to arrhythmia or rapidly progressive heart 
failure, often with a fatal outcome. Fulminant myocarditis can 
be caused by various infectious or exogenous agents, as well as 
immune-mediated conditions. Regardless of the initiating factor, 
the pathogenesis is characterized by a deregulated inflammatory 
response, leading to cardiac damage. This inflammation-mediated 
myocardial damage leads to contractile dysfunction, clinically 
manifested with heart failure. Recent studies indicate that the 
pro-inflammatory cytokine interleukin (IL)-1 is central to the 
development of cardiac inflammation in the pathogenesis of a 
broad spectrum of conditions. Mechanistically, during myocardial 
injury, dying myocardiocytes release various intracellular debris 
and mediators, including IL-1α, which are sensed by resident 
and infiltrating myeloid cells (1). Upon sensing of intracellular 
mediators, the myeloid inflammatory cells activate the “inflam-
masome,” an intracellular molecular complex responsible for the 
processing and release of active IL-1β (2–4). The release of IL-1β 
results in widespread inflammation (5, 6), leading to death of 
cardiomyocytes, progressive loss of viable contractile tissue, and 
development of cardiomyopathy and heart failure (7).
Clinical observations confirm this central role of IL-1 in the 
pathogenesis of cardiac inflammation. In general, myocardial 
involvement is part of the clinical spectrum of inflammatory 
(8–10) or autoinflammatory diseases (11, 12), such as adult-
onset Still’s disease (AOSD) or systemic onset juvenile idiopathic 
arthritis (SOJIA), which are characteristically mediated by IL-1. 
IL-1 receptor blockade is highly effective in these conditions 
(13), as exemplified by several published cases of myocarditis 
associated with SOJIA and AOSD and promptly controlled by 
anakinra (14–17). The clinical picture of this patient, character-
ized by acute biventricular failure with cardiogenic shock and 
robust systemic inflammation, was reminiscent of IL-1-mediated 
autoinflammatory diseases (13). Specifically, the patient had high 
fever and elevated blood neutrophils but no evidence of infection, 
non-ischemic acute collapse of cardiac function compatible with 
myocarditis, and biochemical tests compatible with macrophage 
activation syndrome (multilinear cytopenia and elevated liver 
transaminases and lactate dehydrogenase) (18).
Management of fulminant myocarditis remains a clinical 
challenge, as no specific treatment is available beyond mechanical 
support (19, 20). We had previously treated a patient with life-
threatening viral myocarditis using anakinra, the recombinant 
form of the naturally occurring IL-1 receptor antagonist (21). 
That patient had fulminant viral myocarditis requiring venous-
arterial extracorporeal membrane oxygenation and mechanical 
circulatory support with a left-ventricular assist device, and we 
observed a dramatic clinical response to IL-1 inhibition with 
anakinra.
DIsCUssIoN
The present study reports the dramatic efficacy of IL-1 blockade 
in a case of fulminant myocarditis. The patient had developed 
fulminant myocarditis secondary to the immune activation and 
deregulation induced by an underlying hematologic neoplasm, 
anaplastic T cell lymphoma, which is frequently associated with 
rampant, systemic inflammatory activation (22). Clinically, this 
patient had a progressive collapse of the heart function, despite 
mechanical circulatory support. Given this life-threatening 
condition and the absence of established treatment options for 
fulminant myocarditis beyond mechanical support, we evaluated 
IL-1 inhibition. Treatment with anakinra was started at a stand-
ard subcutaneous dose of 100 mg/day (13, 23). A striking clinical 
improvement was observed within 24 h of treatment initiation. 
Clinical response was initially characterized by a swift reduction 
of fever, neutrophilia (7,000/mm3), CRP (10 mg/L, normal values 
<6), and ferritin (112 ng/mL, normal values 15–150 ng/mL). Over 
the following 2 days, ECG abnormalities also normalized, as did 
troponin T levels (33 ng/L, normal values <38), and the LVEF was 
restored to 50%. After 72 h of daily anakinra, the patient could be 
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weaned from IABP and non-invasive ventilation. Upon clinical 
stabilization, the patient was transferred to the Oncology Unit. 
Anakinra was discontinued, and chemotherapy with a CHOEP 
combination scheme was initiated. Six months after discharge, 
the patient is continuing to receive treatment with chemotherapy 
regimens in an outpatient setting. During this time, repeated car-
diologic monitoring and TTE re-evaluations confirmed complete 
recovery of the LVEF (55%).
In addition to experimental evidence, clinical experience with 
specific IL-1 inhibition provides unambiguous confirmation to 
the role of IL-1 in human myocardial inflammation and heart 
failure. For example, a short course of 14 days of anakinra was 
evaluated in addition to standard of therapy in randomized tri-
als of ST-elevation myocardial infarction (STEMI). Specifically, 
STEMI patients receiving anakinra had reduced left ventricular 
remodeling and were protected from the development of heart 
failure (24). In a different trial evaluating more clinically stable 
patients after reperfused STEMI, anakinra added to optimal 
therapy did not result in remarkable benefits on left ventricular 
remodeling, yet a significant dampening of the systemic inflam-
matory response confirmed the central relevance of IL-1 to the 
sterile heart inflammation associated with STEMI (25). In a 
separate, randomized clinical trial of non-STEMI patients, anak-
inra treatment was again associated with a dampening of serum 
inflammatory markers, thus confirming that IL-1 is a driving 
force of cardiac and systemic inflammation (26).
Given the central role of IL-1 in cardiac inflammation, it is 
not unexpected that treatment with anakinra would curb inflam-
mation and afford significant clinical benefits. However, the 
beneficial effects of IL-1 inhibition on cardiac function extend 
beyond dampening of inflammation and include favorable 
effects on cardiac contractility. Specifically, ex vivo studies with 
human atrial heart strips revealed that IL-1 suppresses contrac-
tile force, even at picomolar concentrations (27). Consistently, 
administration of anakinra to patients with refractory heart 
failure improved exercise tolerance and was associated with a 
corresponding decrease in major pro-inflammatory mediators 
CRP, IL-1β, and IL-6 (28). In a separate double-blind, placebo-
controlled trial, IL-1 inhibition with anakinra 100 mg daily was 
effective also in the management of diastolic heart failure (29). 
This direct beneficial effect of IL-1 blockade on contractile func-
tion likely explains the near-immediate clinical improvement in 
the case described in the present report. This observation is not 
unprecedented, as a single dose of anakinra increased cardiac 
contractility in patients with rheumatoid arthritis within hours 
of administration (30).
Anakinra blocks the biologic activity of both IL-1α and 
IL-1β by competitively inhibiting binding to the interleukin-1 
type I receptor, which is constitutively expressed in most tis-
sues and organs. IL-1α and IL-1β levels are elevated in response 
to inflammatory stimuli. While levels of endogenous IL-1Ra 
are often too low to contain an overwhelming IL-1-mediated 
inflammatory reaction, exogenous administration with anak-
inra suppresses the pathological process. It remains unresolved 
how much of the efficacy of anakinra is attributable to either 
IL-1α or IL-1β inhibition. In this study, we did not determine 
IL-1α or IL-1β levels. However, cytokine levels in patients 
with systemic or local inflammation do not reveal causation, 
regardless of the correlation. Even in patients with established 
IL-1-mediated diseases such as AOSD or SOJIA, the levels are 
often below detection, but the rapid response to anakinra pro-
vides clear evidence for causation. Similarly, a rapid response 
to anakinra indicates a causative role for IL-1-mediated inflam-
mation in myocarditis.
Support measures currently represent the mainstay of 
treatment for fulminant myocarditis (19, 20, 31). In the case 
described in the present report, patient’s heart function had 
swiftly deteriorated and was dependent on mechanical circu-
latory support with IABP; nevertheless, IL-1 inhibition near 
immediately restored cardiac contractility. Caution is advisable 
in ascribing the recovery of patients with fulminant myocarditis 
to specific therapeutic interventions, as spontaneous recovery 
may occasionally occur during mechanical circulatory support. 
Specifically, patients presenting with fulminant myocarditis, 
although more severely ill, may be more likely to fully recover 
than those affected by chronic myocarditis, provided they sur-
vive the acute phase of the disease (32). However, several reasons 
point at a causative role for IL-1 inhibition in the full recovery 
of cardiac function herein described. First, we observed a close 
and striking temporal relation between treatment administra-
tion and recovery, which halted a downward spiraling trend. In 
addition, the concomitant dampening of systemic inflamma-
tion cannot be attributed to mechanical circulatory support. 
Finally, a rationale for IL-1 inhibition in the treatment of heart 
inflammation is evident well beyond our clinical experience in 
the intensive care unit and is supported by sound clinical and 
experimental evidence (33). It remains instead to be determined 
whether the systemic anti-inflammatory effects of treatment 
may have also contributed, at least in part, to promoting cardiac 
recovery.
Important for the administration to the critically ill, anakinra 
has a remarkable record of safety, as a short half-life of 6 h allows 
prompt discontinuation [reviewed in Ref. (13)]. Adverse events 
include injection site reactions and mild-to-moderate neutrope-
nia, which is rapidly reversible upon cessation of treatment.
CoNCLUsIVe ReMaRKs
Regardless of the triggering agent, the inflammatory response in 
myocarditis rapidly escalates into an auto-inflammatory cycle. 
Mechanistically, intracellular contents released from dying myo-
cardiocytes trigger the inflammasome activation and the release 
of IL-1 from neighboring cells, leading to rampant inflammation 
and tissue damage (2). Prompt pharmacologic inhibition of IL-1 
can arrest the progression of uncontrolled inflammation, thus 
preventing extensive damage and restoring cardiac function. 
Given the dual efficacy against myocardial inflammation and 
contractile dysfunction, IL-1 inhibition represents an attractive 
treatment option for conditions characterized by inflammatory 
heart failure.
Interleukin-1 receptor blockade with anakinra is character-
ized by an extremely rapid onset of action and by satisfying safety, 
thus being suitable for the treatment of life-threatening condi-
tions. Indeed, intravenously administered high-dose anakinra 
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was previously evaluated in the treatment of septic shock in three 
controlled trials taking place in the 1990s (34–36). However, 
dated and loose criteria for septic shock lead to the enrollment 
of highly heterogeneous patients, and anakinra did not reach 
statistical significance for reducing all-cause 28-day mortality in 
this setting. Nevertheless, better therapeutic performance was 
observed in patients with the highest risk of death, bacteremia, 
or elevated serum ferritin (36, 37).
Further studies of IL-1 blockade in myocarditis are needed 
to validate use in critically ill patients. Specifically, prospective 
evaluation of a 2-week treatment course with anakinra 100 mg 
daily in addition to conventional life support measures may 
unequivocally assess the impact on acute and mid-term LVEF 
changes. Additional outcome measures of interest include 
survival, requirements for and doses of conventional pharmaco-
logic therapy, assessments of symptoms, and arrhythmias.
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